Delhi and the wider National Capital Region (NCR) form one of India’s largest and most compelling hubs for women’s healthcare. The city is home to a large population of multi-specialty hospitals and dedicated women and child care centres along with fertility clinics that help in serving patients from Delhi and neighbouring states along with helping international medical tourists. As there is growing awareness of reproductive health and gynaecological cancers around urban India, Delhi based hospitals have broaden their obstetrics and gynaecology (Obs & Gynae) departments with modern diagnostics and minimally invasive and robotic surgery along with dedicated fertility (IVF) units.
This guide discusses the top 10 gynaecology hospitals and healthcare companies in Delhi and the market overview for India’s women’s health and fertility market to help patients and researchers understand the present landscape.
Market Overview and Demand Statistics of Gynaecology Companies in Delhi
According to IMARC Group, India’s women’s reproductive health market was valued at around USD 1.1 billion in 2024 and is expected to reach USD 2 billion by 2033 growing at a CAGR of 6.70%. Moreover, the fertility services market of India reached approximately USD 1.50 billion in 2024 and is projected to reach 4.41 billion by 2033 at a CAGR of 12.70%. This is driven by increasing infertility rates and delayed pregnancies along with growing adoption of IVF and related assisted reproductive technologies (ART).
In the same report, industry estimates indicated that around 27.5 million Indian couples at present face difficulty in conceiving naturally and that 10-15% of married couples go through fertility issues nationally.
According to Market Research Future, the India women’s healthcare market was projected at USD 0.85 billion in 2023, growing to an anticipated USD 1.15 billion in 2024 and is estimated to reach USD 3.5 billion by 2035. According to this report, reproductive health management alone was estimated at approximately USD 0.3 billion in 2024 and the infertility segment specifically was projected at USD 0.2 billion in the same year.
Report from Grand View Research state that the Indian Female fertility market produced USD 700.3 million in revenue in 2023 and is estimated to reach USD 1,136.8 million by 2030 at a CAGR of 7.2%. India accounted for approximately 2.5% of the global female infertility market by revenue in 2023 with in vitro fertilization as the largest revenue generating treatment category.
List of Top 10 Gynaecology Companies in Delhi
1. Mankind Pharma – Gynae Division
Headquartered in New Delhi, Mankind Pharma is one of India’s largest pharmaceutical companies and operates a dedicated gynaecology product division known for affordable and effective formulations with strong nationwide market reach. Its gynae portfolio spans hormonal therapies, antifungal preparations, and general women’s health products, backed by one of the country’s largest field-force and distribution networks.
2. Panacea Biotec
Headquartered in New Delhi, Panacea Biotec is a publicly listed pharmaceutical and vaccine manufacturer with a diversified therapeutic portfolio that includes women’s health-related formulations alongside its broader generics and vaccines business. Its scale, R&D capability, and long operating history since 1984 make it one of Delhi’s most established pharmaceutical groups.
3. Indiabulls Pharmaceuticals Ltd.
Based in Connaught Place, New Delhi, and established in 2016, Indiabulls Pharmaceuticals set out to become a leading manufacturer and supplier of quality gynaecology medicines at competitive prices. The company operates GMP-WHO compliant manufacturing and offers a dedicated gynaecology product range, including orosoluble iron sachets and related women’s health formulations, through its PCD franchise model.
4. Gracure Pharmaceuticals Ltd.
Headquartered on Shivaji Marg, New Delhi, since its founding in 1992, Gracure Pharmaceuticals is an integrated pharmaceutical company covering R&D, manufacturing, and marketing. While its core strength spans cardiovascular, gastro-intestinal, and anti-infective medicines, its broader formulation portfolio includes women’s health and gynaecology-related products, and the company exports to over 29 countries from its Delhi corporate base.
5. Systopic Laboratories
Based at Ranjit Nagar, New Delhi, Systopic Laboratories is a long-established Delhi pharmaceutical company (with roughly four decades of operating history) whose therapeutic categories include dermatology, gastroenterology, orthopaedics, cardiology, ENT, and gynaecology. Its diversified multi-specialty portfolio makes it a recognised name among Delhi-based pharma manufacturers with a gynaecology product line.
6. Femcorp (Biocorp)
Femcorp is a Delhi-based Gynaecology PCD company offering exclusive monopoly-based franchise and distribution rights specifically for gynaecology and pro-fertility products. Its offerings are DCGI and FSSAI approved, and the company positions itself as a dedicated gynaecology-only franchise partner for distributors across Delhi and neighbouring regions.
7. Max Life Sciences
Max Life Sciences is a Delhi-based PCD pharma franchise company with a therapeutic portfolio spanning critical care, specialty medicines, and gynaecology, among other categories. The company is frequently featured in industry round-ups of the top PCD pharma companies operating out of Delhi, offering franchise partners marketing materials, legal guidance, and territorial rights.
8. Nava Healthcare
Headquartered at Netaji Subhash Place, Pitampura, New Delhi, Nava Healthcare has built a reputation on a diverse range of tablets and capsules, including formulations for women’s health and gynaecology, as part of its broader PCD pharma franchise offering in Delhi.
9. Pax Healthcare
Pax Healthcare is a Delhi-based PCD pharma company offering franchise opportunities across multiple segments, including gynaecology, anti-infective paediatrics, health supplements, dermatology, and cardiology. The company emphasises innovative formulations developed by its in-house research team as part of its franchise proposition.
10. Biotic Healthcare
Biotic Healthcare is a Delhi-based pharmaceutical company offering monopoly-based PCD pharma franchises across several therapeutic segments, including gynaecology. The company operates with world-class infrastructure for product manufacturing and packaging, and provides incentives and bonuses to franchise partners who meet annual sales targets.
Comparison Table: Top 10 Gynaecology Companies in Delhi
The table below compares the companies profiled above on location, company type, and gynaecology-related focus areas.
| Company | Delhi Location | Company Type | Gynaecology Focus |
| Mankind Pharma (Gynae Division) | New Delhi (HQ) | Large Pharma Corporation | Hormonal therapies, antifungal & women’s health formulations |
| Panacea Biotec | New Delhi (HQ) | Listed Pharma & Vaccine Maker | Women’s health formulations within broader generics portfolio |
| Indiabulls Pharmaceuticals Ltd. | Connaught Place, New Delhi | Pharma Manufacturer (PCD) | Dedicated gynaecology range, iron/fertility sachets |
| Gracure Pharmaceuticals Ltd. | Shivaji Marg, New Delhi (HQ) | Integrated Pharma Company | Women’s health products within multi-therapy portfolio |
| Systopic Laboratories | Ranjit Nagar, New Delhi | Multi-specialty Pharma Company | Gynaecology among 6 therapeutic categories |
| Femcorp (Biocorp) | Delhi-based | Gynae-only PCD Company | Exclusive gynaecology & pro-fertility product range |
| Max Life Sciences | Delhi-based | PCD Pharma Franchise Company | Gynaecology + critical care & specialty segments |
| Nava Healthcare | Pitampura, New Delhi (HQ) | PCD Pharma Franchise Company | Tablets/capsules incl. women’s health formulations |
| Pax Healthcare | Delhi-based | PCD Pharma Franchise Company | Gynaecology + paediatric, derma, cardiology segments |
| Biotic Healthcare | Delhi-based | PCD Pharma Franchise Company | Gynaecology among monopoly-based franchise segments |
Aunexis Pharmaceuticals – A Leading Gynaecology Company
Aunexis Pharmaceuticals is a gynaecology company that has positioned itself as a rapidly growing and dedicated gynaecology medicine company in India. The PCD Company specializes exclusively in women’s healthcare products and provides a wide portfolio across tablets, capsules and other intimate was formulations. Its product range offers major gynaecological requirements that includes hormonal balance support and PCOS/PCOD management long with ovulation and fertility support and menopause symptom relief.
Major highlights of Aunexis Pharmaceuticals include:
- A dedicated women’s health only product portfolio that contains tablets, capsules, gels and other gynaecological products.
- Marketing presence across more than 20 states in India which is supported by an established PCD distribution network along with logistics and franchise partners.
- Exclusive monopoly based distribution rights provided to franchise partners thus offering distributors territory specific exclusivity for Aunexis gynaecology products.
- Manufactured products are aligned with WHO-GMP standards.
- End to end business and marketing support for franchise partners that includes promotional support and training.
Conclusion
Delhi NCR remains one of India’s most well-resourced destinations for gynaecological and women’s healthcare, home to a mix of large hospital chains and long-established independent institutions that together cover the full spectrum of care, from routine gynaecological check-ups and PCOS management to high-risk obstetrics, robotic gynaecological surgery, and gynaecological oncology. This depth of infrastructure is being reinforced by strong underlying demand: India’s women’s reproductive health, fertility services, and IVF markets are all growing at healthy double-digit or high single-digit CAGRs through the early 2030s, driven by rising infertility awareness, delayed parenthood, and expanding access to assisted reproductive technologies.
Pharmaceutical companies such as Aunexis Pharmaceuticals play an equally important, if less visible, role by supplying the gynaecology medicines, hormonal therapies, and fertility-support formulations that make modern gynaecological treatment possible. As demand for women’s healthcare continues to rise across Delhi and the rest of India, both ends of this ecosystem, clinical care providers and gynaecology-focused pharmaceutical companies, are likely to see continued growth and investment in the years ahead.
For distributors and franchise partners evaluating opportunities in this space, the right choice will typically depend on product portfolio breadth, certification standards (WHO-GMP, DCGI, FSSAI), monopoly/territorial rights offered, and the level of marketing and business support provided, factors that are worth verifying directly with each company before entering into a franchise or distribution agreement.
Frequently Asked Questions
How large is the women’s health and fertility market in India?
India’s women’s reproductive health market was valued at approximately USD 1.1 billion in 2024 and is projected to reach USD 2.0 billion by 2033. The broader fertility services market was valued at about USD 1.50 billion in 2024, projected to reach USD 4.41 billion by 2033 (IMARC Group).
Why is demand for gynaecology and fertility services rising in Delhi?
Rising infertility rates, delayed marriages and pregnancies, urban lifestyle factors, increasing PCOS prevalence, and growing awareness of reproductive health are the primary demand drivers nationally, and Delhi NCR, as a major urban centre with dense hospital infrastructure, captures a large share of this growth.
How many couples in India face fertility challenges?
Industry estimates suggest approximately 27.5 million Indian couples currently experience difficulty conceiving, with 10-15% of married couples nationally facing some form of fertility issue, according to IMARC Group’s 2024 industry analysis.
Do Delhi hospitals offer robotic or minimally invasive gynaecological surgery?
Yes. Several hospitals in this list, including Max Saket and BLK-Max, offer robotic and laparoscopic gynaecological surgery for conditions such as ovarian cysts, fibroids, and endometriosis, along with minimally invasive procedures like hysteroscopic myomectomy and Non-Descent Vaginal Hysterectomy (NDVH).
What is the IVF and fertility treatment market outlook in India?
India’s IVF services market was valued at roughly USD 1,410.11 million in 2025 and is projected to reach USD 4,915.01 million by 2034, growing at a CAGR of 16.23%, according to Custom Market Insights, supported in part by government maternal health programs.
How is the female infertility market in India expected to grow?
The India female infertility market generated USD 700.3 million in 2023 and is projected to reach USD 1,136.8 million by 2030, growing at a CAGR of 7.2%, with IVF as the largest revenue-generating treatment segment (Grand View Research).
What kind of company is Aunexis Pharmaceuticals?
Aunexis Pharmaceuticals is a PCD Pharma Company focused exclusively on gynaecology and women’s healthcare products, such as hormonal therapies, PCOS/PCOD management formulations, fertility and prenatal support products, and menopause-relief medicines. It is a manufacturer/marketer of medicines rather than a hospital or clinical care provider.
Does Aunexis Pharmaceuticals treat patients directly?
No. Aunexis Pharmaceuticals does not provide clinical consultations or hospital-based treatment. It manufactures and markets gynaecology medicines and products that are prescribed by gynaecologists, including those practising at hospitals such as the ones listed in this guide.
